None listed
Conditions
Interventions
None listed
Sponsors
Aichi Cancer Center
Flatiron Health K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be included in this study: - Patients who visited Aichi Cancer Center for an initial or follow-up visit between the date of study approval and December 31, 2028 - Patients with a confirmed diagnosis of the following types of cancer - Gastrointestinal cancers (esophageal cancer, gastroesophageal junction cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, gallbladder cancer, duodenal papillary carcinoma, intrahepatic bile duct cancer, gastrointestinal stromal cancer, small bowel cancer (including duodenal cancer), primary neuroendocrine tumor of the digestive tract, etc.) - Breast cancer - Hematopoietic malignancies (leukemia, malignant lymphoma, multiple myeloma, myeloproliferative disorders, etc.) - Lung cancer (non-small cell lung cancer, small cell lung cancer, etc.) - Patients aged 18 and above - Patients who provided appropriate consent to participate in this study.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Real-world overall survival, time-to-next-treatment, progression-free survival, time-to-treatment-discontinuation etc. | — |
Countries
Japan
Contacts
Public ContactKei Muro
Aichi Cancer Center Department of Clinical Oncology
Outcome results
None listed